Immix Biopharma, Inc.
IMMX
$1.99
-$0.42-17.43%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 2.71M | 3.61M | 2.95M | 2.48M | 2.34M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 4.68M | 4.99M | 7.39M | 4.70M | 5.59M |
Operating Income | -4.68M | -4.99M | -7.39M | -4.70M | -5.59M |
Income Before Tax | -4.53M | -4.80M | -7.14M | -4.40M | -5.32M |
Income Tax Expenses | 9.80K | 10.80K | 11.10K | 10.30K | 8.80K |
Earnings from Continuing Operations | -4.54M | -4.81M | -7.15M | -4.41M | -5.33M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | 0.00 | -- | 12.90K | 72.10K |
Net Income | -4.54M | -4.81M | -7.15M | -4.39M | -5.26M |
EBIT | -4.68M | -4.99M | -7.39M | -4.70M | -5.59M |
EBITDA | -4.64M | -4.97M | -7.39M | -4.70M | -5.59M |
EPS Basic | -0.15 | -0.16 | -0.24 | -0.15 | -0.22 |
Normalized Basic EPS | -0.10 | -0.10 | -0.15 | -0.10 | -0.14 |
EPS Diluted | -0.15 | -0.16 | -0.24 | -0.15 | -0.22 |
Normalized Diluted EPS | -0.10 | -0.10 | -0.15 | -0.10 | -0.14 |
Average Basic Shares Outstanding | 29.70M | 29.56M | 29.42M | 28.79M | 23.44M |
Average Diluted Shares Outstanding | 29.70M | 29.56M | 29.42M | 28.79M | 23.44M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |